Economic evaluation of antipsychotic drugs for schizophrenia treatment within the Brazilian Healthcare System
DOI:
https://doi.org/10.1590/S0034-89102009000800010Keywords:
Antipsychotic Agents, Schizophrenia, Health Care Costs Quality-Adjusted Life Years, Single Health System, Cost-Effectiveness EvaluationAbstract
OBJECTIVE: To assess the cost-utility of first and second-generation antipsychotics for treatment of schizophrenia. METHODS: A five-year Markov model was constructed based on a survey of the records of patients seen in 2006 at a psychosocial care center in the municipality of Florianopolis, Southern Brazil. Costs were evaluated from the perspective of the Sistema Único de Saúde (SUS - Unified Healthcare System). Utility was measured in quality-adjusted life years obtained in the literature. RESULTS: The Markov model indicated risperidone and haloperidol utilization before olanzapine as the most cost-effective alternatives. CONCLUSIONS: Antipsychotic agents haloperidol and risperidone are more cost-effective than olanzapine. Strategies prioritizing the use of antipsychotics with better cost-effectiveness could optimize resource allocation without necessarily compromising the health of patients treated through the Sistema Único de Saúde.Downloads
Published
2009-08-01
Issue
Section
Original Articles
How to Cite
Lindner, L. M., Marasciulo, A. C., Farias, M. R., & Grohs, G. E. M. (2009). Economic evaluation of antipsychotic drugs for schizophrenia treatment within the Brazilian Healthcare System . Revista De Saúde Pública, 43(suppl.1), 62-69. https://doi.org/10.1590/S0034-89102009000800010